Media coverage about Summit Therapeutics (NASDAQ:SMMT) has trended somewhat positive on Saturday, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Summit Therapeutics earned a daily sentiment score of 0.24 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.0532410057126 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Summit Therapeutics (NASDAQ SMMT) traded up $0.26 during midday trading on Friday, reaching $12.17. The company’s stock had a trading volume of 30,009 shares, compared to its average volume of 32,161. The stock has a market cap of $164.90, a PE ratio of -121.70 and a beta of 0.37. Summit Therapeutics has a 52-week low of $8.80 and a 52-week high of $16.86.
Summit Therapeutics (NASDAQ:SMMT) last released its quarterly earnings results on Wednesday, December 6th. The company reported ($0.20) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.73) by $0.53. Summit Therapeutics had a negative return on equity of 10.90% and a negative net margin of 0.95%. equities analysts predict that Summit Therapeutics will post -0.59 EPS for the current fiscal year.
A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Summit Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. HC Wainwright set a $16.00 target price on Summit Therapeutics and gave the stock a “buy” rating in a report on Wednesday, December 27th. ValuEngine cut Summit Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. SunTrust Banks assumed coverage on Summit Therapeutics in a report on Thursday, January 4th. They set a “buy” rating and a $24.00 target price for the company. Finally, Oppenheimer reiterated a “buy” rating and set a $24.00 target price on shares of Summit Therapeutics in a report on Monday, October 16th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $21.20.
ILLEGAL ACTIVITY NOTICE: “Summit Therapeutics (SMMT) Given Daily News Impact Score of 0.24” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/01/21/summit-therapeutics-smmt-earning-somewhat-favorable-media-coverage-study-shows.html.
Summit Therapeutics Company Profile
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.